美國(guó) . Adimab

總部位于新罕布什爾州Lebanon的Adimab公司關(guān)注的是蛋白質(zhì)藥品。通過(guò)此次投資，Google Ventures的比爾·麥瑞斯(Bill Maris)將成為Adimab公司董事。他表示，先進(jìn)的生命科學(xué)技術(shù)是極度計(jì)算密集型，Google Ventures將投入大量資金，幫助Adimab公司成為世界領(lǐng)先的抗體公司。

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Conventional antibody discovery is a lengthy process that involves a myriad of different technologies that need to be assembled before a commercial antibody can be produced. The integration of: (i) library design, (ii) display methodology, (iii) reformatting between different hosts and expression constructs, and (iv) GMP cell line development is resource intensive, time consuming, and typically results in extensive royalty obligations to multiple third parties.

Adimab was founded by two of the world's leading yeast biotechnologists: Professor Tillman Gerngross (Dartmouth, Co-founder of GlycoFi, Inc., a wholly owned subsidiary of Merck & Co. since 2006) who led the humanization effort to engineer yeast for the production of human glycoproteins, and Professor Dane Wittrup (MIT, Co-founder of Biodisplay, acquired by Abbott Labs in 2001.) who pioneered yeast surface display for the discovery and maturation of antibody fragments.